Dysmenorrhea in adolescents and young adults: From pathophysiology to pharmacological treatments and management strategies

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 15, 2008, Pages 2661-2672

  Harel, Zeev ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Adolescents; Endometriosis; Primary dysmenorrhea; Young adults

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; CELECOXIB; DEPO SUBQ PROVERA; DICLOFENAC; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; EXEMESTANE; GONADORELIN AGONIST; HERBACEOUS AGENT; IBUPROFEN; IMMUNOMODULATING AGENT; INDOMETACIN; KETOPROFEN; LETROZOLE; LEVONORGESTREL; MATRIX METALLOPROTEINASE INHIBITOR; MECLOFENAMATE SODIUM; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; MONTELUKAST; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE ACETATE; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PLACEBO; SEASONIQUE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOMEPIRAC;

ACUPUNCTURE; ADD ON THERAPY; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOMETRIOSIS; HUMAN; HYPERTHERMIC THERAPY; INCIDENCE; LAPAROSCOPY; LOADING DRUG DOSE; LOW DRUG DOSE; MENSTRUAL CYCLE; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; TRANSCUTANEOUS NERVE STIMULATION; UTERUS DISEASE;

ABDOMINAL PAIN; ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DYSMENORRHEA; FEMALE; HUMANS; RISK FACTORS; YOUNG ADULT;

EID: 55249083797     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.15.2661     Document Type: Review

References (100)

1. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981;68:661-4
2. Hillen TI, Grbavac SL, Johnston PJ, et al. Primary dysmenorrhea in young western Australian women: prevalence, impact and knowledge of treatment. J Adolesc Health 1999;25:40-5
3. O'Connell K, Davis AR, Westhoff C. Self-treatment patterns among adolescent girls with dysmenorrhea. J Pediatr Adolesc Gynecol 2006;19:285-9
4. Harlow SD, Park M. A longitudinal study of risk factors for the occurrence, duration, and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynecol 1996;103:1134-42
5. Balbi C, Musone R, Menditto A, et al. Influence of menstrual factors and dietary habits on menstrual pain in adolescence age. Eur J Obstet Gynecol Reprod Biol 2000;91:143-8
6. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. Eur J Clin Nutr 1995;49:508-16
7. Hornsby PP, Wilcox AJ, Weinber CR. Cigarette smoking and disturbance of menstrual function. Epidemiology 1998;9:193-8
8. Laufer MR. Identification of clear vesicular lesions of atypical endometriosis: a new technique. Fertil Steril 1997;68:739-40
9. Simpson JL, Bischoff FZ, Kamat A, et al. Genetics of endometriosis. Obstet Gynecol Clin N Am 2003;30:21-40
10. James AH. More than menorrhagia: a review of the obstetric and gynaeological manifestations of bleeding disorders. Haempohilia 2005;11:295-307
11. Alvin PE, Litt IF. Current status of etiology and management of dysmenorrhea in adolescents. Pediatrics 1982;70:516-25
12. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-63
13. Chan WY, Hill JC. Determination of menstrual prostaglandin levels in nondysmenorrheic and dysmenorrheic subjects. Prostaglandins 1978;15:365-75
14. Rees MCP, Anderson ABM, Demers LM, et al. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhea. Br J Obstet Gynaecol 1984;91:673-80
15. Lundstrom V, Green K. Endogenous levels of prostaglandin F2 and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 1978;130:640-6
16. Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006;108(2):428-41
17. Rees MCP, Di Marzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhea and menorrhagia. J Endocrinol 1987;113:291-5
18. Levinson SL. Peptidoleukotriene binding in guinea pig uterine membrane preparations. Prostaglandins 1984;28:229-40
19. Nigam S, Benedetto C, Zonca M, et al. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids 1991;4:137-41
20. Harel Z, Lilly C, Riggs S, et al. Urinary Leukotriene (LT)-E4 in adolescents with dysmenorrhea. J Adolesc Health 2000;27:151-4
21. Valentin L, Sladkevicius P, Kindahl H, et al. Effects of a vasopressin antagonist in women with dysmenorrhea. Gynecol Obstet Invest 2000;50:170-7
22. Cameron IT, Cambell S. Nitric oxide in the endometrium. Hum Reprod Update 1998;4:565-9
23. Gazvani R, Templeton A. Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 2002;123:217-26
24. Bulun SE, Yang S, Fang Z, et al. Estrogen production and metabolism in endometriosis. Ann NY Acad Sci 2002;955:75-85
25. Matsuzaki S, Murakami T, Uehara S, et al. Expression of estrogen receptor alpha and beta in periotaneal and ovarian endometriosis. Fertil Steril 2004;75:1198-205
26. Keenan JA, Chen TT, Chadwell NL, et al. IL-1 beta, TNF-alpha and IL-2 in peritoneal fluid and macrophage-conditioned media of women with endometriosis. Am J Reprod Immunol 1995;34:381-5
27. Ota H, Igarashi S, Sasaki M, et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 2001;16:561-6
28. Tamura M, Deb S, Sebastian S, et al. Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 2004;81:1351-6
29. Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600-6
30. Zeitoun K, Takayama K, Sasano H, et al. Deficient 17B-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize estradiol-17B. J Clin Endocrinol Metab 1998;83:4474-80
31. Chapron C, Fauconnier A, Dubuisson JB, et al. Deep infiltrating endometriosis; relation between severity of dysmenorrhea and extent of disease. Hum Reprod 2003;18:760-6
32. Fedele L, Parazzini F, Bianchi S, et al. Stage and localization of pelvic endometriosis and pain. Fertil Steril 1990;53:155-8.
33. Goldstein DP, DeCholnoky C, Emans SJ. Adolescent endometriosis. J Adolesc Health Care 1980;1:37-41
34. Menon S, Sammel MD, Vichnin M, et al. Risk factors for ectopic pregnancy: a comparison between adults and adolescent women. J Pediatr Adolesc Gynecol 2007;20:181-5
35. Kotani N, Sakai I, Hashimoto H, et al. Analgesic effect of an herbal medicine for treatment of primary dysmenorrhea - a double blind study. Am J Chin Med 1997;25:205-12
36. Kaplan B, Rabinerson D, Lurie S, et al. Clinical evaluation of a new model of transcutaneous electrical nerve stimulation device for the management of primary dysmenorrhea. Gynecol Obstet Invest 1997;44:255-9
37. Steinberger A. The treatment of dysmenorrhea by acupuncture. Am J Chin Med 1981;9:57-60
38. Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001;97:343-9
39. Golub LJ, Menduke H, Lang WR. Exercise and dysmenorrhea in young teenagers: a 3-year study. Obstet Gynecol 1968;32:508-11
40. Barnard ND, Scialli AR, Hurlock D, et al. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet Gynecol 2000;95:245-50
41. Harel Z, Biro FM, Kotenhahn RK, et al. Supplementation with omega-3 fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8
42. Chan WY, Dawood MY. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res 1980;8:1443-7
43. Hanson FW, Izu A, Henzyl MR. Naprosyn sodium in dysmenorrhea: its influence in allowing work/school activities. Obstet Gynecol 1978;52:583-7
44. Budoff PW. Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. N Engl J Med 1982;307:714-9
45. Smith RP, Powell JR. Intrauterine pressure changes during dysmenorrhea therapy. Am J Obstet Gynecol 1982;143:286-92
46. Mehlisch DR. Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison. J Clin Pharmacol 1998;28:S29-33
47. Mehlisch DR. Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. Clin Ther 1990;12:398-409
48. Marchini M, Tozzi L, Bakshi R, et al. Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double blind, within-patient, placebo-controlled study. Int J Clin Pharmacol Ther 1995;33:491-7
49. Boctor AM, Eickolt M, Pugsley TA. Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cycloxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med 1986;23:229-338
50. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Am J Obstet Gynecol 1984;148:96-103
51. Roy S. A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet Gynecol 1983;61:628-32
52. DuRant RH, Jay MS, Shofitt T. Factors influencing adolescents' responses to regimens of naproxen for dysmenorrhea. Am J Dis Child 1985;139:489-93
53. Harel Z. Cyclooxygenase (COX)-2 specific inhibitors in the treatment of dysmenorrhea. J Pediatr Adolesc Gynecol 2004;17:75-9
54. Dawood M. Non-steroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med 1988;84:23-9
55. Harel Z, Riggs S, Vaz R, et al. The use of the leukotriene receptor antagonist montelukast (Singulair) in the management of dysmenorrhea in adolescents. J Pediatr Adolesc Gynecol 2004;17:183-6
56. Bieglmayer C, Hofer G, Kainz C, et al. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995;9:307-12
57. Hauksson A, Akerlund M, Forsling ML, et al. Plasma concentrations of vasopressin and a prostaglandin F2α metabolite in women with primary dysmenorrhea before and during treatment with a combined oral contraceptive. J Endocrinol 1987;115:355-61
58. Creatsas G, Deligeoroglou E, Zachari A, et al. Prostaglandins: PGFα, PGE2, 6-keto-PGF1α and TXB serum levels in dysmenorrheic adolescents before, during and after treatment with oral contraceptives. Eur J Obstet Gynecol Reprod Biol 1990;36:292-8
59. Ekstrom P, Juchnicka E, Laudanski T, et al. Effect of an oral contraceptive in primary dysmenorrhea - changes in uterine activity and reactivity to agonists. Contraception 1989;40:39-47
60. Ekstrom P, Akerlund M, Forsling M, et al. Stimulation of vasopressin release in women with primary dysmenorrhea and after oral contraceptive treatment - effect on uterine contractility. Br J Obstet Gynaecol 1992;99:680-4
61. Milsom I, Andersch B. Effect of various oral contraceptive combinations on dysmenorrhea. Gynecol Obstet Invest 1984;17:284-92
62. Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46:327-34
63. Robinson JC, Plichata S, Weisman CS, et al. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol 1992;166:578-83
64. Ulstein M, Svendsen E, Steier A, et al. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand 1984;63:233-6
65. Weber-Diehl F, Unger R, Lachnit U. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception 1992;46:19-27
66. Davis AR, Westhoff C, O'Connell K, et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005;106:97-104
67. Louden NR, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 1997;2:487-90
68. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-83
69. Guillebaud J. Reducing withdrawal bleeds. Lancet 2000;355:2168-9
70. Ortiz A, Hiroi M, Stancyk FZ, et al. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA. J Clin Endocrinol Metab 1977;44:32-8
71. Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004;70:11-8
72. Harel Z, Biro F, Kollar L. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health 1995;16:379-84
73. Depo-Provera 'Black Box Warning' Available from: http://www.fda.gov/ medwatch/SAFETY/2004/DepoProvera_Label.pdf [Accessed 27 January 2005]
74. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health 2006;39:296-301
75. Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena®): a 3-year follow-up study. Contraception 2003;67:87-91
76. Mirena product insert, 2008. Available from: www.mirena-us.com/ index.html?WT.srch=1 [Accessed 18 July 2008]
77. Funk S, Miller MM, Mishell DR, et al. Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319-26
78. Harel Z, Riggs S, Vaz R, et al. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol 2005;18:85-90
79. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal ring, NuvaRing®: results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2007;28:1-8
80. ACOG Committee on Adolescent Health Care Opinion No. 310. Endometriosis in Adolescents. Obstet Gynecol 2005;105:921-7
81. Moore J. Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 1997;4:CD001019. DOI:10.1002/14651858;CD001019
82. Lubianca JN, Gordon CM, Laufer MR. "Add-back" therapy fore endometriosis in adolescents. J Reprod Med 1998;43:164-72
83. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99:709-19
84. DiVasta AD, Laufer MR, Gordon CM. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J Pediatr Adolesc Gynecol 2007;20:293-7
85. Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate; a pilot study. Fertil Steril 2004;81:290-6
86. Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005;84:300-4
87. Attar E, Bulun SE. Aromatase inhibitors: The next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307-18
88. Buzdar AU, Robertson JF, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the new generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-16
89. Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast 2004;(Suppl 13):10-8
90. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38
91. Chlouber RO, Olive DL, Pritts EA. Investigational drugs for endometriosis. Invest New Drugs 2006;15:399-407
92. Cook AS, Rock JA. Role of laparoscopy in the treatment of endometriosis. Fertil Steril 1991;55:663-80
93. Propst AM, Laufer MR. Endometriosis in adolescents: incidence, diagnosis, and treatment. J Reprod Med 1999;44:751-8
94. Jacobson TZ, Barlow DH, Garry R, et al. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001;4:CD001300, doi:10.1002/14651858
95. Strawbridge LC, Crouch NS, Cutner AS, et al. Obstructive mullerian anomalies and modern laparoscopic management. J Pediatr Adolesc Gynecol 2007;20:195-200
96. Cox DJ, Meyer RG. Behavioral treatment parameters with primary dysmenorrhea. J Behav Med 1978;1:297-310
97. Chatman DL, Ward AB. Endometriosis in adolescents. J Reprod Med 1982;27:156-60
98. Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005;4:CD004753
99. Doyle JO, Missmer SA, Laufer MR. The effect of standard medical-surgical intervention on progression of endometriosis. J Pediatr Adolesc Gynecol 2008;21:64-5
100. Sanfilippo JS, Wakim NG, Schikler KN, et al. Endometriosis in association with uterine anomaly. Am J Obstet Gynecol 1986;154:39-43